Elicio Therapeutics, Inc. (ELTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 7, 2024, concerns Elicio Therapeutics, Inc., a Delaware corporation. The report details the outcome of the Company's virtual Annual Meeting of Stockholders held on November 7, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary event reported is the adjournment of the Annual Meeting due to the absence of a quorum of common stockholders. Despite the lack of a quorum, a majority of the shares represented by proxies actually received were voted in favor of each proposal intended for submission.
Outlook and Management Commentary
- Reconvened Meeting: The Annual Meeting will be reconvened on Thursday, November 21, 2024, at 9:30 a.m. Eastern Time via remote communications only.
- Voting Procedures: Stockholders must preregister by 11:59 p.m. Eastern Time on Wednesday, November 20, 2024, to attend. Previously delivered proxies remain valid for the reconvened meeting.
- Record Date: The record date remains the close of business on September 11, 2024.
Key Facts for Investor Verification
- Verify the reconvened meeting date: November 21, 2024.
- Confirm preregistration deadline: November 20, 2024, at 11:59 p.m. ET.
- Note that the meeting will be virtual only; no physical location is available.
- Check if previously submitted proxies are still valid for the new date (they are).